Profound Medical is a medical device company and an innovator in interventional MRI (iMRI) procedures that enable precise, incision-free therapies that improve doctors’ clinical confidence and procedural control as well as patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.
TULSA-PRO® is our flagship platform, enabling MRI-guided, incision-free prostate therapy designed for precision and flexibility. The TULSA Procedure™ allows doctors to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and erectile dysfunction.
Profound’s Sonalleve® is an MRI-guided therapy that provides a non-surgical treatment option for pain relief of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis.
TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy—expanding access to precise, personalized, and incision-free treatment options worldwide.
For more information, visit the Profound Medical website.